Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Condition:   NorovirusInterventions:   Biological: Norovirus GI.1/GII.4 Bivalent VLP Vaccine;   Drug: 0.9% sodium chloride (saline)Sponsor:   TakedaNot yet recruiting - verified January 2016

Source: ClinicalTrials.gov - January 8, 2016 Category: Research Source Type: clinical trials